Our mission is to revolutionise ADC development
Antibody Drug Conjugates (ADCs) represent a powerful addition to cancer treatment, with a mechanism that permits the delivery of potent cytotoxic agents directly to cancer cells using monoclonal antibodies that target tumour-specific antigens.
This selective approach to delivery of tumour killing payloads results in superior efficacy and fewer side effects for patients.
Currently, there are over 80 ADCs in the clinic, comprised of a selection of toxin classes, numerous linkers and a wide range of antibodies, directed towards many distinct antigens.
Iksuda’s approach is straightforward – we are focused on the targeted delivery of potent, next generation DNA damaging payloads to solid cancers to treat the broadest patient population possible.
Improving therapeutic index